Effectiveness and Safety of Tocilizumab, an Anti-Interleukin-6 Receptor Monoclonal Antibody, in a Patient With Refractory GI Graft-Versus-Host Disease

被引:37
作者
Gergis, Usama [1 ]
Arnason, Jon [1 ]
Yantiss, Rhonda [1 ]
Shore, Tsiporah [1 ]
Wissa, Usama [1 ]
Feldman, Eric [1 ]
Woodworth, Thasia [2 ]
机构
[1] Weill Cornell Med Coll, New York, NY USA
[2] Roche Prod Ltd, Welwyn Garden City AL7 3AY, Herts, England
关键词
CELL TRANSPLANTATION; ANTI-CD3; ANTIBODY; IL-6; MULTICENTER; VISILIZUMAB; BLOCKADE; COLITIS; TRIAL;
D O I
10.1200/JCO.2010.29.1682
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
[No abstract available]
引用
收藏
页码:E602 / E604
页数:3
相关论文
共 13 条
[1]
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation:: Evidence in Crohn disease and experimental colitis in vivo [J].
Atreya, R ;
Mudter, J ;
Finotto, S ;
Müllberg, J ;
Jostock, T ;
Wirtz, S ;
Schütz, M ;
Bartsch, B ;
Holtmann, M ;
Becker, C ;
Strand, D ;
Czaja, J ;
Schlaak, JF ;
Lehr, HA ;
Autschbach, F ;
Schürmann, G ;
Nishimoto, N ;
Yoshizaki, K ;
Ito, H ;
Kishimoto, T ;
Galle, PR ;
Rose-John, S ;
Neurath, MF .
NATURE MEDICINE, 2000, 6 (05) :583-588
[2]
A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease [J].
Carpenter, PA ;
Appelbaum, FR ;
Corey, L ;
Deeg, HJ ;
Doney, K ;
Gooley, T ;
Krueger, J ;
Martin, P ;
Pavlovic, S ;
Sanders, J ;
Slattery, J ;
Levitt, D ;
Storb, R ;
Woolfrey, A ;
Anasetti, C .
BLOOD, 2002, 99 (08) :2712-2719
[3]
A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease [J].
Carpenter, PA ;
Lowder, J ;
Johnston, L ;
Frangoul, H ;
Khoury, H ;
Parker, P ;
Jerome, KR ;
McCune, JS ;
Storer, B ;
Martin, P ;
Appelbaum, F ;
Abonour, R ;
Westervelt, P ;
Anasetti, C .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2005, 11 (06) :465-471
[4]
Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease [J].
Chen, Xiao ;
Das, Rupali ;
Komorowski, Richard ;
Beres, Amy ;
Hessner, Martin J. ;
Mihara, Masahiko ;
Drobyski, William R. .
BLOOD, 2009, 114 (04) :891-900
[5]
Treatment of steroid-refractory acute graft-versus-host disease with anti-CD147 monoclonal antibody ABX-CBL [J].
Deeg, HJ ;
Blazar, BR ;
Bolwell, BJ ;
Long, GD ;
Schuening, F ;
Cunningham, J ;
Rifkin, RM ;
Abhyankar, S ;
Briggs, AD ;
Burt, R ;
Lipani, J ;
Roskos, LK ;
White, JM ;
Havrilla, N ;
Schwab, G ;
Heslop, HE .
BLOOD, 2001, 98 (07) :2052-2058
[6]
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].
Emery, P. ;
Keystone, E. ;
Tony, H. P. ;
Cantagrel, A. ;
van Vollenhoven, R. ;
Sanchez, A. ;
Alecock, E. ;
Lee, J. ;
Kremer, J. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523
[7]
HEBART H, 1995, BONE MARROW TRANSPL, V15, P891
[8]
Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation [J].
Holler, E ;
Rogler, G ;
Herfarth, H ;
Brenmoehl, J ;
Wild, PJ ;
Hahn, J ;
Eissner, G ;
Schölmerich, J ;
Andreesen, R .
BLOOD, 2004, 104 (03) :889-894
[9]
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease [J].
Ito, H ;
Takazoe, M ;
Fukuda, Y ;
Hibi, T ;
Kusugami, K ;
Andoh, A ;
Matsumoto, T ;
Yamamura, T ;
Azuma, J ;
Nishimoto, N ;
Yoshizaki, K ;
Shimoyama, T ;
Kishimoto, T .
GASTROENTEROLOGY, 2004, 126 (04) :989-996
[10]
An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens [J].
Leisenring, Wendy M. ;
Martin, Paul J. ;
Petersdorf, Effie W. ;
Regan, Anne E. ;
Aboulhosn, Nada ;
Stern, Jean M. ;
Aker, Saundra N. ;
Salazar, Raymond C. ;
McDonald, George B. .
BLOOD, 2006, 108 (02) :749-755